Aprea Therapeutics (Aprea Therapeutics) Ending Cash Position : $32.41 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Ending Cash Position?

Aprea Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $32.41 Mil.

Aprea Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 ($25.39 Mil) to Dec. 2023 ($21.65 Mil) but then increased from Dec. 2023 ($21.65 Mil) to Mar. 2024 ($32.41 Mil).

Aprea Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($53.08 Mil) to Dec. 2022 ($28.79 Mil) and declined from Dec. 2022 ($28.79 Mil) to Dec. 2023 ($21.65 Mil).

Aprea Therapeutics Ending Cash Position Historical Data

The historical data trend for Aprea Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics Ending Cash Position Chart

Aprea Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

130.09

89.02

53.08

28.79

21.65

Aprea Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															31.00	27.73	25.39	21.65	32.41

Aprea Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Aprea Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	28.787	+	-7.139
	=	21.65

Aprea Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	21.647	+	10.764
	=	32.41

Aprea Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprea Therapeutics (Aprea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

3805 Old Easton Road, Doylestown, PA, USA, 18902

Website

https://www.aprea.com

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Executives

Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill	officer: SrVP/CFO/Prin. Fin &Acctg. Off	4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger	director	C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey	director	27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad	officer: President, CEO	535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu	director	535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade	director, officer: President & CEO	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar	officer: SVP, Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel	officer: Chief Business Officer	535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen	officer: SVP, Chief Scientific Officer	535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107